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The aim of this work was to improve fluconazole flowability by wet granulation and to study the effect of 
granulation on drug dissolution from tablets and capsules. Fluconazole was submitted to a process of wet 
granulation in a high-speed granulator using PlasdoneÒ K29/32 or K90. Flow properties of granules and 
dissolution profiles for tablets and capsules produced with them were determined. Fluconazole granules 
demonstrated better flowability, calculated by angle of repose and compressibility index data, compared 
with powder. Additionally, it was observed that the granulation process improved the dissolution efficiency 
(ED) of fluconazole from tablets and capsules, which could also suggest an increase in bioavailability. 
Higher dissolution efficiencies were achieved with Plasdone® K29/32.
Uniterms: Fluconazole/flowability. Tablets/dissolution. Capsules/dissolution. PlasdoneÒ
O objetivo deste trabalho foi melhorar as características de fluxo do fluconazol com o emprego da 
granulação úmida e estudar o efeito desse processo na dissolução do fármaco em cápsulas e comprimidos. 
O fluconazol foi submetido ao processo de granulação úmida num granulador de alta velocidade 
empregando PlasdoneÒ K29/32 e K90. Foram determinadas as propriedades de fluxo dos grânulos e obtidos 
os perfis de dissolução de cápsulas e comprimidos obtidos com os granulados em estudo. Os grânulos 
de fluconazol apresentaram melhores características de fluxo após o processamento, demonstradas por 
meio das determinações do ângulo de repouso e do índice de compressibilidade, comparativamente à 
matéria-prima. Adicionalmente, observou-se que o processo de granulação melhorou a eficiência de 
dissolução (ED) do fluconazol nos comprimidos e cápsulas.
Unitermos: Fluconazol/capacidade de fluxo. Comprimidos/dissolução. Cápsulas/dissolução. PlasdoneÒ.
INTRODUCTION
Fluconazole is a broad-spectrum antifungal agent, 
active by both oral and intravenous routes, for the treat-
ment of superficial and systemic infections (Richardson et 
al., 1990). FCZ is a triazole that has established an excep-
tional therapeutic record for Candida infections including 
oropharyngeal and esophageal candidiasis, vulvovaginal 
candidiasis, candidemia and disseminated candidiasis 
(Cha, Sobel, 2004).
This drug presents a reasonable solubility and is 
more hydrophilic than other azole derivatives used as 
antifungals where this leads to better absorption from the 
gastrointestinal tract (Kowalsky, Dixon, 1991). Porta, 
Chang, Storpirtis, (2005) and Pereira et al., (2004) have 
evaluated the bioavailability and bioequivalence of com-
mercial capsule formulations of fluconazole available 
on the Brazilian market. In both studies, the commercial 
capsules were considered bioequivalent to the reference 
product.
FCZ presents very poor flowability yet there are no 
studies in the literature about this characteristic. Regarding 
the manufacturability of tablets, good flowability of the 
blend, i.e. the mixture of excipients and drug, is critical for 
compression in terms of dissolution, friability and content 
uniformity (Martinello et al., 2006). One way to improve 
the flowability of drugs and to make tablet production 
feasible is by using the wet granulation process. Granu-
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lation in a high shear mixer is a common method used in 
the production of granules. The main reasons for this are 
that high shear granulation produces spherical and well-
compacted granules in a relatively short time and that the 
equipment is of relatively simple construction and easily 
cleaned (Albertini et al., 2003). 
There are many excipients that can be used as bin-
der agents. Amongst them, cellulose derivatives, starch 
paste and PVP are the most usually applied (Lachman, 
Lieberman, Kanig, 2001). Wet granulation with binders 
can improve the flowability of the drug but can also affect 
its dissolution behavior. Except for bioequivalence studies, 
there is a lack of studies evaluating the effect of excipients 
in fluconazole dissolution from tablets. Studying the su-
ppository form, Nair and Barghava (1999) evaluated the 
dissolution of fluconazole from hydrophilic, lipophilic, and 
amphiphilic bases. Additionally, the drug is only commer-
cially available in Brazil as capsules in an oral dosage form.
For this reason, the aim of the present work was to 
produce granules of fluconazole with improved flowabi-
lity, and to evaluate the effect of this process on the drug 
dissolution from tablets and capsules. Granules were 
prepared by wet granulation in a high shear mixer using 
PVP with different viscosities.
MATERIAL AND METHODS
Material
Fluconazole (SP Farma, FLP 0040102, India), 
Polyvinylpyrrolidone (Plasdone® K29/32 and K90/D, 
International Specialty Products, USA), Microcrystalline 
cellulose (Microcel® MC-101, Blanver, USA), Sodium 
Croscarmellose (Explocel®, Blanver, USA), Magnesium 
stearate (Natural Pharma, Brazil) were all of pharmaceutical 
grade. Hydrochloric acid (HCl 37% Merck, USA) and other 
reagents were of analytical grade. Fluconazole (>99%) was 
used as standard in quantitative determinations.
Granulation process
FCZ was submitted to a process of wet granulation in 
a high-speed granulator (Diosna High Shear Granulation. 
Dierks & Söhne GmbH) under the following operating 
conditions: initial and final speed of the chopper were 350 
and 500 rpm, respectively; initial and final speed of the 
impeller were 500 and 700 rpm, respectively. A solution 
of 20% Plasdone® K29/32 or 10% Plasdone® K90 was 
employed as the binder agent. Both granulates (FCZPK30 
and FCZPK90, with PVP K30 and PVP K90, respectively) 
were selected in a conical screen cone mill (Quadro Comil-
I Square Engineering Inc., I Model U3-005, Waterloo-
Canada) with a sieve of 4.0 mm. Granules were led into 
a fluid bed dryer (Diosna Minilab Fluid Bed Dryer) with 
operating temperatures of 99 ºC for the entrance air and 
60 ºC for the exit air, until a loss on drying value of less 
than 5% was obtained. Granules were then sieved through 
a 1.4 -1.5 mm mesh.
Flowability studies and assay of FCZ in granules
The flow speed was observed by the drainage time of 
100 g of fluconazole and of fluconazole granules through 
a perforated disk measuring 10.0 mm in diameter, in an 
Erweka GT Flow Analyser. The angle of repose and the 
flow were calculated by the equipment.
For the determination of bulk and tap densities, a 
volume of approximately 50 mL of fluconazole (FCZ) 
and fluconazole granules (FCZ K30 and FCZ K90) was 
individually transferred to a 100 mL test tube. The volume 
was then read directly to calculate the bulk density (r
bulk
) 
according to the mass/volume ratio. For tap density (r
tap
), 
the test tube was tapped about 3000 times, until volume 
was constant, using a Logan TAP-2 tap density analyzer. 
Compressibility was calculated using the equation (Lach-
man, Lieberman, Kanig, 2001): 
The amount of fluconazole in granules was spectro-
photometrically determined at 260 nm (Bechmam Coulter, 
DU640) in water, using the analytical curve (r2 = 0.9974) 
from an in house pre-validated method (Equation 2).
Preparation of the formulations as capsules or 
tablets 
Tablets were produced in a 10 mm single-punch 
tablet press (Fabbe), with a compression force of 3000 
kg, after mixing powders and fluconazole granules in an 
Apex-Multipex biconical mixer. Capsules (n° 1) with the 
same compositions were prepared by manual filling. The 
compositions of capsules and tablets are shown in Table I. 
EQUATION 1 - Percent compressibility (%); bulk density, r
bulk 
(g∕mL); tap density, r
tap 
(g∕mL).
 y = 0.0021x + 0.0012
EQUATION 2 - Analytical curve of the validated spectro-
photometric method, at 260 nm, in water (data not shown).
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The average weight was obtained over 20 units, according to 
United States Pharmacopoeia (2008) and Farmacopéia Bra-
sileira (1988) methods. The coefficients of variation (CV) 
were calculated. For each formulation, the friability was 
evaluated over a sample of 20 tablets. According to official 
specifications, hardness could not be less than 5 Kgf, and 
for friability, the acceptance criterion was a maximum loss 
of 1.5% of the initial weight (Farmacopéia Brasileira, 1988).
Dissolution test
The dissolution tests were accomplished in a dis-
solution tester (Logan instruments corp., I Model D-800) 
applying the following conditions (Porta, Chang, Storpirtis, 
2005): apparatus 1 (basket), speed of 75 rpm, 900 mL of 
0.01 N HCl solution at 37 ± 0.5oC. The filtered aliquots of 10 
mL were removed from each vessel at 5, 10, 15, 20, 25 and 
30 minutes, with immediate replacement of fresh medium. 
The percentages of drug dissolved were determined by re-
cording each sample in a spectrophotometer at 260 nm, and 
dissolution profiles of FCZ during the test were obtained.
The dissolution efficiencies (DE%) were determi-
ned for the ratio among the area under the dissolution 
curves, between the times zero and 30 minutes (ASC
0-30
) 
calculated applying the trapezoidal method, and the total 
area of the rectangle (ASC
TR
) defined for the ordinate 
(100% of dissolution) and for the abscissa (t=30 minutes) 
(Khan, Rhodes, 1975). Dissolution efficiency values were 
submitted to analysis of variance (ANOVA) to evaluate 
significant differences among the dissolution profiles. 
RESULTS AND DISCUSSION
Fluconazole granules and flowability studies
Among the many particles properties required in the 
production of solid dosage form, flowability is essential to 
ensure a successful tabletting process. Powder flowability 
is influenced by many factors such as particle size, size dis-
tribution, shape, surface texture, surface energy, chemical 
composition, moisture content, vessel geometry and other 
factors. A common and easy method widely employed in 
the pharmaceutical industry for flowability measurement 
is the tapping test (Li et al., 2004; Nokhodchi et al., 2007).
According to Zatloukal and Sklubalová (2007), in 
order to evaluate the flow rate of a layer of material flowing 
uniformly from the outlet of a cylindrical hopper, the rela-
tionship to the bulk density of the powder is more useful 
than the tapped density which represents the properties of 
the stagnant layer of non-flowing material at the periphery 
of the hopper.
The flowability was evaluated for fluconazole and 
granules by the angle of repose, percentage compressibili-
ty and also by direct determination of the flow through a 10 
mm diameter hole. Bulk and tap densities of powder and 
granules were used to calculate the compressibility index 
(%). The flowability data are shown in Table II. The com-
pressibility and angle of repose were indirect measures of 
the flow and lower values for these parameters indicate 
better flowability. 
The production of granules of fluconazole with 
PVP (Plasdone® K29/32 and Plasdone® K90) improved 
TABLE I - Compositions of capsules and tablets produced with fluconazole (FCZ), and fluconazole granules (FCZ K30 and FCZ K90).
Formulation Fluconazole Magnesium stearate Croscamelose Microcrystalline 
cellulose 
Capsule composition (%)
FCZ 42.86 1.00 1.50 54.64
FCZ K30 47.46 1.00 1.50 50.04
FCZ K90 45.30 1.00 1.50 52.20
Tablet composition (%)
FCZ 42.86 1.00 3.00 53.14
FCZ K30 47.46 1.00 3.00 48.54
FCZ K90 45.30 1.00 3.00 50.70
TABLE II - Flowability characteristics of fluconazole (FCZ) and 
fluconazole granules produced with Plasdone® K29/32 (FCZ 
K30) or Plasdone® K90/D (FCZ K90). N=3
Flow (g/s) Angle of 
repose (a)
Compressibility 
(%)
FCZ nd nd 38.78
FCZ K30 12.10 39.8 11.54
FCZ K90 13.29 39.9 12.96
nd = not determined
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angle of repose, flow and compressibility of fluconazole. 
No significant difference between the two binder agents 
was observed based on these characteristics. However, 
different amounts of binder agents were used to produce 
granules: about 10% PVP K29/32 and approximately 5% 
PVP K90. Therefore, as expected, PlasdoneÒ K90 presented 
a more efficient binder capacity than K29/32, because of 
its viscosity.
Wan et al. (1996), using PVP K29/32 and K90 as 
binder agents in the production of propranolol granules, 
observed that PVP of higher molecular weight such as 
Plasdone® K90, provided stronger bonds to the granules 
and thus enabled them to better withstand the effects of 
attritive forces generated during fluidized bed granulation.
The amount of fluconazole was determined in the 
granules by an in-house validated spectrophotometric 
procedure using the equation obtained by the analytical 
curve. Granules produced with Plasdone® K29/32 (FCZ 
K30) presented 90.26% FCZ, and the content of flucona-
zole in granules produced with Plasdone® K90 (FCZ K90) 
was 94.62%. 
Dosage forms and dissolution studies
Capsules and tablets were prepared taking into ac-
count the fluconazole content in the granules. The average 
weight, hardness, and friability of tablets were obtained 
according to USP 31 ed. (2008) and Farmacopéia Brasi-
leira (1988) as shown in Tables III and IV.
The friability of tablets met the requirements (no 
greater than 1.5% mass loss). The values for hardness and 
average weight of the tablets obtained for the fluconazole 
and granules were also within the requirements. However, 
the coefficient of variation (CV) of FCZ tablets was very 
high, while values obtained for the fluconazole granules 
were lower. This indicates that besides poor flowability, 
which led to uniform filling of the matrix, fluconazole 
presented reduced compressing capability.
Dissolution profiles of FCZ from capsules and 
tablets produced with FCZ and FCZ granules (FCZ K30 
and FCZ K90) were obtained according to Porta, Chang, 
Storpirtis (2005). The drug concentrations of each sample 
were determined by spectrophotometry at 260 nm and the 
percentages of FCZ dissolved are shown in Table V. 
The dissolution efficiencies (DE) were calculated 
from zero to 30 minutes (ASC 0-30), and these results 
TABLE III - Average weight data of capsules and tablets produced 
with fluconazole (FCZ) and granules (FCZ K30 and FCZ K90). 
N=20
Formulation Weight (g)
Capsules FCZ 0.352 (1.3)
FCZ K30 0.389 (1.4)
FCZ K90 0.375 (2.4)
Tablets FCZ 0.318 (5.3)
FCZ K30 0.305 (1.2)
FCZ K90 0.295 (1.2)
Coefficients of variations (%) are between parentheses. 
TABLE IV – Hardness and friability data of tablets produced with 
fluconazole (FCZ) and granules (FCZ K30 and FCZ K90). N=20
Tablets Hardness (Kgf) Friability (%)
FCZ 7.10 (87.1) 0.39
FCZ K30 6.41 (10.2) 0.20
FCZ K90 6.50 (9.3) 0.16
Coefficients of variations (%) are between parentheses.
TABLE V – Percentages of drug dissolved for capsules and tablets produced with fluconazole (FCZ) and granules (FCZ K30 and 
FCZ K90). N=4
Time (min) % fluconazole dissolved
Capsules Tablets
FCZ FCZ K30 FCZ K90 FCZ FCZ K30 FCZ K90
5 7.3 (21.9) 44.4 (6.4) 46.8 (2.4) 4.3 (19.3) 55.2 (9.6) 41.4 (13.3)
10 17.7 (19.1) 69.1 (5.0) 64.8 (1.1) 10.6 (11.6) 72.5 (8.5) 60.7 (6.9)
15 23.2 (18.3) 89.9 (2.6) 72.9 (3.3) 13.5 (8.0) 86.4 (7.5) 73.8 (4.9)
20 32.6 (24.0) 94.2 (1.9) 77.4 (4.1) 16.7 (5.3) 91.1 (2.9) 84.2 (9.4)
25 40.7 (26.3) 96.4 (1.6) 78.7 (4.1) 19.4 (4.3) 92.3 (2.6) 85.9 (2.8)
30 46.7 (24.0) 97.3 (2.2) 79.0 (4.5) 22.4 (3.9) 93.0 (2.1) 87.5 (2.2)
Coefficients of variations (%) are between parentheses. 
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were submitted to analysis of variance (ANOVA) which 
expressed significant differences among them (Table VI).
The dissolution profiles of the drug are summarized 
in Figures 1 and 2. The releases of fluconazol from tablets 
produced with the granules (FCZ P30 and FCZ P90) were 
much faster than releases from tablets produced with 
FCZ. Similar results were found for capsules. All tablets 
and capsules disintegrated rapidly at the beginning of the 
dissolution process, offering more surface area available 
for dissolution. More than 60% of the drug was released 
within 10 min for all formulations produced with granules, 
in contrast to those obtained with FCZ, which released 
only 17.7% (capsules) and 10.6% (tablets). Dissolution 
efficiency data (Table VI) shows that capsules and tablets 
produced with FCZ presented similar dissolution behavior 
to that of an extended-release formulation. This finding is 
in accordance with the studies of Orelli and Leuenberger 
(2004) who found similar results in a study on release from 
tablets produced with granules of proquazone. These au-
thors considered this dissolution behavior a characteristic 
of poorly wettable drugs. Therefore, fluconazole can be 
characterized as a poorly wettable drug and consequently, 
the increased dissolution rate seen in the granule form can 
be explained by the higher wettability achieved by the 
addition of the hydrophilic excipient. 
Greater improvement in dissolution efficiency was 
observed when PVP K29/32 was used. Similar results were 
observed by Albertini et al. (2003) in piroxicam granules 
or physical mixtures with PVP K12 and PVP K90, where 
the improvement of dissolution was more significant with 
the use of PVP of lesser molecular weight. This could be 
explained by the higher viscosity of PVP K90 leading to 
stronger bonds in granules. Additionally, the drug probably 
had to pass through a more viscous layer to be released, 
when PVP K90 was used.
No studies were available on the flowability pro-
perties of fluconazole, but the results from flow, angle of 
repose and compressibility clearly indicated that direct 
TABLE VI - Dissolution efficiency of fluconazole from capsules 
and tablets produced with FCZ and granules (FCZ K30 and 
FCZ K90). N=4
Formulation Dissolution efficiency (%)
Capsules Tablets
FCZ 34.33 (26.7) 12.61 (4.7)
FCZ K30 74.24 (1.9) 73.99 (4.4)
FCZ K90 63.35 (3.9) 64.96 (7.0)
Coefficients of variation (%) are between parentheses.
FIGURE 2 - Drug dissolution profile of tablets produced with 
fluconazole (FCZ) and granules (FCZ K30 and FCZ K90).
FIGURE 1 - Drug dissolution profile from capsules with 
fluconazole (FCZ) and fluconazole granules (FCZ K30 and 
FCZ K 90).
compression is not possible with this drug. The powder 
did not flow through the hole in the equipment and repose 
angle and flow were not determined. Taking into account 
that direct compression presents many advantages over 
other techniques, especially by decreasing the number of 
stages in the manufacturing process, it would be advanta-
geous to use pre co-processed powder containing a large 
amount of drug for direct compression.
In conclusion, under these experimental conditions, 
the fluconazole granulation process was found to improve 
drug flowability, resulting in lower CVs for tablet and 
capsule characteristics, and also enhanced dissolution 
efficiency by increasing powder wettability. The capsules 
of fluconazole with Plasdone® K29/32 presented a disso-
lution profile of over 85% after 30 minutes, considered a 
satisfactory for immediate release dosage forms. Given 
the significant improvement in the dissolution rate for 
all dosage forms prepared with fluconazole granules, an 
associated increase in drug bioavailability is likely.
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